Phospho-STMN1 (Ser25) Antibody

1. Research suggests that activating autophagy reduces the expression of STMN1 and p53, contributing to the anti-cancer effects of Halofuginone by inhibiting cancer cell migration and invasion. These findings might provide new insights into breast cancer prevention and treatment. PMID: 29231257
2. A study found that low expression of STMN1 was present in 43.62% and high expression in 56.38% of osteosarcoma cases. High tumor expression of STMN1 was identified as a prognostic marker for poor prognosis, poor response to chemotherapy, metastasis, advanced Enneking surgical stage, and the chondroblastic osteosarcoma subtype. STMN1 expression was determined to be an independent prognostic biomarker for osteosarcoma. PMID: 30169496
3. A transcription-independent mechanism for Stat3-mediated centrosome clustering has been identified involving Stathmin, a Stat3 interactor involved in microtubule depolymerization, and the mitotic kinase PLK1. PMID: 28474672
4. Findings suggest that stathmin is essential for bipolar spindle formation, ensuring genomic stability during mitosis. Depleting stathmin prevents the onset of chromosome instability by inducing senescence in human normal fibroblasts. PMID: 28885720
5. Research indicated that STMN1 overexpression was significantly associated with lymphatic metastatic recurrence in pN0 esophageal squamous cell carcinoma (ESCC) patients. STMN1 levels are regulated by the PI3K pathway, and STMN1 can serve as a surrogate marker for PI3K pathway signaling related to tumor recurrence. PMID: 29251330
6. The investigation confirmed a correlation between stathmin expression and more aggressive behavior of cervical cancer. PMID: 29953794
7. High STMN1 expression is linked to cancer progression and chemo-resistance in lung squamous cell carcinoma. PMID: 28933054
8. STMN1 expression showed a significant association with prognosis and tumor differentiation in ESCC, indicating that STMN1 expression serves as an independent prognostic factor for ESCC and could potentially be a biomarker. Regulating STMN1 expression could influence tumor cell motility, invasion, and proliferation. PMID: 29039594
9. T3-mediated suppression of STMN1 supports the theory that T3 plays an inhibitory role in HCC tumor growth. This suggests that the lack of normal THR function leads to elevated STMN1 expression and malignant growth. PMID: 27934948
10. Results suggest that stathmin acts as an oncogene and is transcriptionally regulated by mutant p53, but not by wild-type p53. Stathmin could be a potential anti-tumor therapeutic target in oral squamous cell carcinoma. PMID: 28806997
11. Findings suggest that Stathmin 1 (STMN1) plays a significant role in cell proliferation and migration. PMID: 27349455
12. STMN1 expression was higher in basal-type cell lines compared to luminal-type cell lines. Overall survival and post-progression survival were shorter in high STMN1 expression breast cancer patients than in those with low STMN1 expression. High STMN1 expression is a potential marker of breast cancer aggressiveness, linked to proliferation, phenotype, and cancer stem cell type. PMID: 28766688
13. An upregulated expression of STMN1 was observed in the atypical/anaplastic meningioma group relative to the benign meningioma group. Therefore, STMN1 is a promising target to improve cure rates in meningioma cases. PMID: 28625575
14. An increased risk of sporadic atypical meningioma recurrence was found in cases with elevated expression of STMN1. PMID: 28622584
15. The miR-34a/STMN1/betaIII-tubulin axis maintains the microtubule cytoskeleton in osteosarcoma. Combining miR-34a with microtubule inhibitors could be investigated as a novel therapeutic strategy. PMID: 28275089
16. These findings suggest that Cdc2 is positively associated with the development of taxol resistance. The Cdc2 inhibitor, purvalanol A, enhanced the cytotoxic effects of taxol through Op18/stathmin. PMID: 28534969
17. Research showed that stathmin expression was significantly up-regulated in LAC, which may serve as a biomarker for LAC. Additionally, silencing stathmin inhibited LAC cell growth, indicating that stathmin might be a promising molecular target for LAC therapy. PMID: 27494889
18. Increased stathmin correlated with pathological grade, lymphatic invasion, advanced stage, and poor survival of non-small cell lung cancer (NSCLC), suggesting that stathmin could serve as a potential biomarker for NSCLC. PMID: 28282798
19. Patients with cancer displayed a higher stathmin expression compared to non-cancer individuals. Overexpression of stathmin correlated with tumor cell differentiation, lymph node invasion, and high TNM stage. [review] PMID: 27806343
20. High STMN1 expression is associated with tumor differentiation and metastasis in pancreatic cancer. PMID: 29374725
21. miR-223 might serve as an onco-suppressor that enhances susceptibility to docetaxel by downregulating STMN1 in gallbladder cancer, highlighting its promising therapeutic value. PMID: 27577078
22. Overexpression of STMN1 correlates with poorer prognosis and interacts with p53 in oral squamous cell carcinoma. PMID: 27591090
23. A study elucidated a novel Malat1-miR-101-STMN1/RAB5A/ATG4D regulatory network where Malat1 activates autophagy and promotes cell proliferation by sponging miR-101 and upregulating STMN1, RAB5A, and ATG4D expression in glioma cells. PMID: 28834690
24. STMN1 gene and miRNA-223 expression profiles in non-tumor liver tissues were predictive of the risk for multicentric hepatocellular carcinoma recurrence. PMID: 28982915
25. The crucial role of FOXM1 and STMN1 in TKI-induced enrichment of CSC and drug resistance was demonstrated by knockdown of STMN1 and FOXM1 in NSCLC cells. PMID: 28850563
26. Research indicates that RSK2 directly phosphorylates stathmin and regulates microtubule polymerization, providing a pro-invasive and pro-metastatic advantage to cancer cells. Therefore, the RSK2-stathmin pathway represents a promising therapeutic target and a prognostic marker for metastatic human cancers. PMID: 27041561
27. Stathmin expression was significantly associated with shorter progression-free survival and overall survival for all analyzed cases of endometrial cancer. These findings demonstrate that high stathmin expression is a poor prognostic marker in endometrial cancer. PMID: 28532857
28. STMN1 is a potential biomarker for paclitaxel sensitivity and poor prognosis in gastric cancer (GC) and could be a novel therapeutic target in metastatic GC. PMID: 28334732
29. STMN1, COF1, and PAIRBP1 represent proteins associated with proliferative and aggressive tumors of high grades, while TSP2 and POSTN were connected to low-grade tumors with better prognosis. PMID: 28216224
30. The phosphorylation-specific association of STMN1 with GRP78 promotes breast cancer metastasis. PMID: 27130664
31. These results suggest that STMN1 plays an important role in the proliferation and migration of hypopharyngeal squamous cell carcinoma and could potentially be used as a prognostic biomarker or therapeutic target for hypopharyngeal squamous cell carcinoma (HSCC). PMID: 27878293
32. High STMN1 expression is associated with invasion in endometrial carcinoma. PMID: 26815505
33. High expression of stathmin 1 predicts poor outcome in oral squamous cell carcinoma patients treated with docetaxel-containing regimens. PMID: 26590596
34. The expressions of TYMS, TUBB3, and STMN1 were significantly associated with the clinicopathological characteristics of age, gender, and family history of gastric cancer but not with differentiation, growth patterns, metastasis, and TNM staging in patients with gastric cancer. PMID: 28056823
35. Stathmin is a highly sensitive and specific biomarker for diagnosing vulvar high-grade squamous intraepithelial lesions. PMID: 27226646
36. Silencing STMN1 by siRNA may enhance the sensitivity of esophageal cancer cells Eca-109 to paclitaxel and induce apoptosis. PMID: 26782519
37. SNP in the STMN1 gene may have a potential predictive role in taxane-based chemotherapy for advanced non-small cell lung cancer. PMID: 26148901
38. After silencing stathmin-1 in gastric cancer cells, the resistance index was reduced. PMID: 26802649
39. Results indicate that the STMN1-E/P/C signature is a reliable prognostic indicator for luminal subtype breast cancer and may predict the therapeutic response to paclitaxel-based treatments, potentially facilitating individualized management. PMID: 26087399
40. STMN1 may play a significant role in the development and tumor progression of cutaneous squamous cell carcinoma. PMID: 26235036
41. Studies suggest that phosphorylation of stathmin controls its biological activity by reducing its affinity for tubulin and hence preventing microtubule disassembly. PMID: 26450904
42. FANCC interacts and co-localizes with STMN1 at centrosomes during mitosis. Research also showed that FANCC is required for STMN1 phosphorylation. PMID: 26466335
43. PDAC patients with higher STMN1 expression experienced a shorter lifespan than those with lower STMN1 expression. PMID: 25791566
44. Stathmin-1 may play a crucial role in regulating trophoblast invasion. PMID: 26272359
45. These results suggest that SEPTIN2-mediated cytoskeletal rearrangement and STATHMIN-mediated differentiation may contribute to changes in cell morphology and differentiation of H/RS cells with CD99 upregulation in Hodgkin lymphoma. PMID: 26000982
46. miR-223 regulates STMN1 in malignant pleural mesothelioma, and both are in turn regulated by the JNK signaling pathway. Therefore, miR-223 and STMN1 play a significant role in regulating MPM cell motility. PMID: 25824152
47. Research reports that STMN1 is a highly sensitive marker for leiomyosarcoma but is suboptimally specific for diagnostic purposes. PMID: 26045786
48. MiR-101 sensitizes human nasopharyngeal carcinoma cells to radiation by targeting stathmin 1. PMID: 25607713
49. High levels of stathmin exhibited a poor response to chemotherapy (for mRNA, P = 0.041; for protein, P = 0.017). Overexpression of stathmin was associated with shorter overall survival (for mRNA, P = 0.012) and progression-free survival. PMID: 25894372
50. STMN1 overexpression is associated with drug resistance in esophageal squamous cell carcinoma. PMID: 25944168

Show More

Hide All

HGNC: 6510

OMIM: 151442

KEGG: hsa:3925

STRING: 9606.ENSP00000410452

UniGene: Hs.209983